German rebate exemptions under threat
This article was originally published in Scrip
Exemptions for struggling pharma companies from the obligatory rebates that all firms must offer German health insurers are under scrutiny from the European Commission. The commission has opened an investigation into the opt-outs, claiming they could be in breach of EU guidelines on state aid for rescuing and restructuring companies in financial difficulties.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.